---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-062058"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T23:00:44.650289+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Liminatus Pharma advances IBA101 CD47 inhibitor toward IND submissions in H2 2026

## Summary
- Completed GLP toxicology studies at Charles River; no clinically meaningful hemoglobin or platelet reductions in primates.
- Plans simultaneous IND submissions to FDA and Korea's MFDS in H2 2026; site activations and patient screening start early 2027.
- Partnered with Dr. Se-Hoon Lee at Samsung Medical Center for Phase 1 trial in NSCLC, including 3+3 dose-escalation and PD-1/PD-L1 combination arms.
- Preclinical combination data with PD-1/PD-L1 inhibitors showed increased complete response rates versus monotherapy.
- Engineered epitope selectivity and Fc modifications designed to avoid anemia/thrombocytopenia that halted earlier CD47 programs.

## SEC filing metadata
- accession: 0001104659-25-062058
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465925062058/0001104659-25-062058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465925062058/tm2518817d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-062058
- JSON: https://secwatch.observer/filing/0001104659-25-062058.json
- Plain text: https://secwatch.observer/filing/0001104659-25-062058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.